

RESEARCH ARTICLE

Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β -peptide deposition: Insights into the effects of in vivo treatment with *N*-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease

Renā A. S. Robinson¹, Gururaj Joshi¹, Quanzhen Huang¹, Rukhsana Sultana¹, Austin S. Baker¹, Jian Cai², William Pierce², Daret K. St. Clair³, William R. Markesbery^{4,5†} and D. Allan Butterfield^{1,4,6}

¹ Department of Chemistry, University of Kentucky, Lexington, KY, USA

² Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY, USA

³ Department of Toxicology, University of Kentucky, Lexington, KY, USA

⁴ Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA

⁵ Department of Neurology, University of Kentucky, Lexington, KY, USA

⁶ Center of Membrane Sciences, University of Kentucky, Lexington, KY 40506, USA

Proteomics analyses were performed on the brains of wild-type (WT) controls and an Alzheimer's disease (AD) mouse model, APP/PS-1 human double mutant knock-in mice. Mice were given either drinking water or water supplemented with *N*-acetylcysteine (NAC) (2 mg/kg body weight) for a period of five months. The time periods of treatment correspond to ages prior to A β deposition (i.e. 4–9 months), resembling human mild cognitive impairment (MCI), and after A β deposition (i.e. 7–12 months), more closely resembling advancing stages of AD. Substantial differences exist between the proteomes of WT and APP/PS-1 mice at 9 or 12 months, indicating that A β deposition and oxidative stress lead to downstream changes in protein expression. Altered proteins are involved in energy-related pathways, excitotoxicity, cell cycle signaling, synaptic abnormalities, and cellular defense and structure. Overall, the proteomic results support the notion that NAC may be beneficial for increasing cellular stress responses in WT mice and for influencing the levels of energy- and mitochondria-related proteins in APP/PS-1 mice.

Received: August 19, 2011

Revised: July 21, 2011

Accepted: August 18, 2011



Keywords:

APP/PS1 / Alzheimer disease / Animal proteomics / Mild cognitive impairment / *N*-Acetylcysteine / Oxidative stress / Protein oxidation

Correspondence: Professor D. Allan Butterfield, Department of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center of Aging, University of Kentucky, Lexington, KY 40506, USA

E-mail: dabcn@uky.edu

Fax: +1-859-257-5876

Abbreviations: AD, Alzheimer's disease; APP, amyloid precursor protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GDH, glutamate dehydrogenase 1; GS, glutamine synthetase; HNE, 4-hydroxynonenal; MCI, mild cognitive impairment; PS-1, presenilin 1; SOD2, superoxide dismutase 2; WT, wild-type

1 Introduction

As the number of persons in the United States directly affected by Alzheimer's disease (AD) is expected to increase in the next 40 years to an estimated 16–20 million persons [1], the need for preventative or modulatory therapies is pressing. While there are many types of compounds being explored as potential AD treatments, the oxidative stress

[†]Deceased on January 30, 2010.

Colour online: See the article online to view Fig. 3 in colour.

hypothesis associated with AD has brought to the forefront the possible therapeutic utility of antioxidant compounds. This is based on the observed increase in reactive oxygen species (ROS) in AD brain that leads to downstream increases in protein oxidation [2], DNA and RNA oxidation [3–7], and lipid peroxidation [8–9]. The oxidative stress present in AD brain is also a result of decreased endogenous antioxidant defenses [10–11] and ultimately leads to neuronal death. Because of the profound consequences of oxidative stress in AD brain and reports that high doses of compounds such as α -tocopherol (vitamin E) may be effective in delaying disease progression [12], the potential of antioxidant compounds as AD therapeutics seems promising.

Our laboratory has provided substantial evidence that amyloid-beta ($A\beta$) (1–42), known to be heavily implicated in AD, mediates oxidative stress in AD brain [13]. $A\beta$ (1–42) is derived from the amyloid precursor protein (APP) through cleavage of APP by β - and γ -secretases, in which presenilin 1 (PS-1) is a component of the γ -secretase complex. Genetic mutations in APP, PS-1, and PS-2 are associated with familial AD (FAD) [14]. PS-1 mutations lead to altered processing of APP and thus an increase in $A\beta$ peptides which are present as toxic oligomers or in senile plaques, pathological hallmarks of AD.

A mammalian model of FAD was developed by Borchelt et al. (licensed to Cephalon, Frazer, PA, USA), in which mice were backcrossed to carry the $APP^{NLh}/APP^{NLh} \times PS-1^{P264L}/PS-1^{264L}$ mutations in order to humanize the mouse $A\beta$ sequence and to include the PS-1 mutation identified in human AD (APP/PS-1 human double mutant knock-in mice) [15]. APP/PS-1 mice have increased $A\beta$ production and accelerated amyloid deposition [15]. We have shown that neurons from APP/PS-1 mice (generated using the Cre-loc[®] knock-in technology) compared to wild type (WT) exhibit increased protein oxidation, lipid peroxidation, and susceptibility to oxidation by exogenous oxidants [16]. Furthermore, cerebral amyloid deposition increases in an age-dependent manner in APP/PS-1 mice [17–19]. Oxidative stress levels (as measured by protein carbonyls (PCO), 3-nitrotyrosine (3NT)-modified proteins, markers of protein oxidation, and 4-hydroxynonenal (HNE)-bound proteins, a marker of lipid peroxidation) also increase in brain in an age-dependent manner in APP/PS-1 knock-in mice when compared to WT controls [20].

We recently explored the antioxidant, N-acetylcysteine (NAC), as an AD treatment at different disease stages in an APP/PS-1 human double mutant knock-in mouse model [21]. NAC is currently an FDA-approved drug for acetaminophen-based liver toxicity [22] and heavy metal poisoning. NAC serves as an antioxidant by indirectly increasing intracellular glutathione (GSH) levels and also acts directly as a free radical scavenger. Depletion of GSH is associated with many neurodegenerative disorders, includ-

ing AD [11, 23, 24]; however, dietary or pharmacological agents/mimetics that increase endogenous GSH levels can provide neuroprotection against oxidative stress [7, 13, 25]. That NAC increases endogenous GSH levels and protects brain from protein oxidation against hydroxyl radicals has been previously demonstrated in vivo [26]. NAC has also been shown to be partially protective in brain against peroxynitrite-induced damage [27] and protective against 3-nitropropionic acid [28] and acrolein-induced protein oxidation [29]. Furthermore, NAC restores memory and decreases oxidative stress in aged senescence-prone mice [30].

As noted above, NAC provides protection against oxidative stress in the brains of APP/PS-1 human double mutant knock-in mice [21]. In those studies, drinking water was supplemented with NAC and administered daily to WT and APP/PS-1 mice for a period of five months beginning at ages of 4- and 7-months old. These ages correlate with the progression of amyloid deposition which begins at the age of 9 months, with elevated $A\beta$ (1–42) deposition in frank deposits occurring at 12 months [17–19]. By 9 months of age, $A\beta$ (1–42) deposition begins in APP/PS-1 mouse brain [19] and thus mimics pathological conditions of amnesic mild cognitive impairment (MCI), a transitional stage between normal aging, early dementia, and AD [31, 32] or early AD. Overall, in this previous study NAC provided neuroprotection against protein oxidation and nitration both prior to amyloid deposition (i.e. 9-month-old animals) and after amyloid deposition (i.e. 12-month-old animals) in APP/PS-1 human double mutant knock-in mice relative to WT [21]. In addition NAC treatment protected against lipid peroxidation when administered in the earlier age group [21]. Thus, NAC may potentially prevent some of the oxidative stress accompanying MCI and early stages of AD as well as reverse oxidative damage found during later stages of AD.

Herein, we seek to gain insights into the mechanisms reflective of $A\beta$ deposition and mechanisms governing the neuroprotection NAC provides against oxidative stress in the brains of APP/PS-1 human mutant double knock-in mice (hereafter referred to as APP/PS-1). To this end, proteomics analyses of the brains from 9- and 12-month-old WT and APP/PS-1 mice treated five months in vivo with or without NAC in the drinking water were performed. We hypothesized that (i) the brain proteome of APP/PS-1 mice at 9 months of age (beginning of $A\beta$ deposition) and 12 months of age (frank amyloid deposits) are different from WT mice, and (ii) in vivo NAC treatment causes changes in brain protein levels that are consistent with subsequent decreases in oxidative stress. 2-D PAGE coupled with MS analysis and database searching was used to detect differences in protein expression. The results are discussed with relevance to the effect $A\beta$ deposition has on the brain proteome and with relevance to potential in vivo NAC treatment in MCI and AD.

2 Materials and methods

2.1 Chemicals

Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2 Animals and NAC administration

WT and APP/PS-1 human double mutant male mice were housed in the University of Kentucky Central Animal Facility. The APP/PS-1 mice were generated using the Cre-lox[®] knock-in technology by Cephalon and backcrossed to carry the APP^{NLh}/APP^{NLh} × PS-1^{P264L}/PS-1^{264L} mutations in order to humanize the mouse A β sequence and to include the PS-1 mutation identified in human AD [33, 34]. All animals were ~30 g in size at the start of the experiments and were fed standard Purina rodent laboratory chow ad libitum on a 12 h light/dark cycle. Animals, both WT and APP/PS-1 mice, were provided with either drinking water or a 0.001% solution of NAC in drinking water (pH 7.2) for a period of 5 months. Treatments began with one group of animals at 4 months and a second group of animals at 7 months. These times were chosen based on previous studies [35–36], which correlate with A β deposition. As noted, the mice employed begin to deposit A β at 9 months of age. Thus, the 4–9-month period investigated brain prior to A β deposition. These mice have frank amyloid deposition at 12 months of age. Thus, the 7–12-month period investigated NAC treatment during and after A β deposition had begun and plaques had formed. New NAC solutions were provided every other day. Mice consumed ~4 to 5 mL of water per day which amounts to a daily cumulative NAC dose of 2 mg/kg (body weight). Animals from both age groups were sacrificed after 5 months of treatment and brains were flash frozen with liquid nitrogen and stored at –80°C until further use.

2.3 Preparation of brain homogenate

Brains were homogenized using 20 passes of a Wheaton tissue homogenizer into an ice-cold lysing buffer containing 4 μ g/mL leupeptin, 4 μ g/mL pepstatin, 5 μ g/mL aprotinin, 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES (pH 7.4). Homogenates were centrifuged at 20 000 \times g for 10 min and the pellet was suspended in PBS. Pellet suspensions were washed twice with PBS by centrifugation at 32 000 \times g for 10 min. The supernatants were used in other studies of enzymatic activity [21]. The BCA method was used for protein concentration (Pierce, Rockford, IL, USA).

Brain homogenates (150 μ g) were treated with 4 \times volume of 2N HCl at room temperature for 30 min. For protein precipitation, ice-cold 100% trichloroacetic acid was added to a final concentration of 15% trichloroacetic acid

and allowed to react on ice for 10 min. Solutions were centrifuged at 14 000 \times g for 5 min at 4°C, and precipitates were washed with 0.5 mL of 1:1 ethanol:ethyl acetate v/v four times by centrifugation at 14 000 \times g for 3 min at 4°C. The protein pellets were then reconstituted in 200 μ L of a rehydration buffer containing 8 M urea, 2 M thiourea, 50 mM DTT, 2% w/v CHAPS, 0.2% v/v Biolytes, and bromophenol blue. After one to two hours of mild vortexing, protein samples were ready for the first dimension of isoelectric focusing (IEF).

2.4 2-DE

Protein samples were loaded onto 11 cm, pH 3–10 Ready-IPG Strips (Bio-Rad, Hercules, CA, USA). After one hour, 2 mL of mineral oil was added to protein wells to reduce solvent evaporation. Proteins were taken up into strips by active rehydration at 50 V for 16–18 h. The conditions for IEF were as follows: 300 V for 1 h, a linear gradient to 8000 V for 5 h and finally, 20 000 V for 1 h. Focused strips were stored at –80°C until the second dimension of gel electrophoresis was performed. For SDS-PAGE, thawed strips were equilibrated for 15 min in a buffer containing 50 mM Tris-HCl (pH 6.8), 6 M urea, 1% w/v SDS, 30% v/v glycerol, and 0.5% DTT. Next, strips were reequilibrated in the same buffer containing 4.5% iodoacetamide rather than DTT. Strips were placed into Linear Gradient (8–16%) Precast Criterion Tris-HCl gels (Bio-Rad) and run at 200 V for ~65 min.

2.5 SYPRO ruby staining

Following electrophoresis, gels were removed from the gel cassettes and placed in fixing solution (7% acetic acid v/v, 10% methanol v/v, in water) for 45 min on a rocker. Gels were submerged in SYPRO Ruby fluorescent gel stain (Bio-Rad) and allowed to shake overnight on a rocker. SYPRO Ruby was then removed and gels were stored in deionized water.

2.6 Image and statistical analysis

SYPRO Ruby-stained gels were scanned using a STORM phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA) at excitation and emission wavelengths of 470 and 618 nm, respectively, and also saved in a TIFF format. PD-Quest (Bio-Rad) imaging software was then used to match and align protein spots across the gels from the different treatment groups. In these experiments, a single 2-D gel was generated and analyzed for each biological replicate. Protein spots were normalized to the total density detected in each individual gel image. Proteins were considered to be statistically different between treatment groups based on a ≥ 1.5 -

fold-change and a p -value < 0.05 (using a Student's t -test). It should be noted that herein we only assessed changes that occur between treatment groups at each time point independently (i.e. only 4–9 months or only 7–12 months). For example, in the 4–9-month-aged group, we made two way comparisons as follows: (i) WT given drinking water (WT H₂O) versus WT given NAC-supplemented water (WT NAC), (ii) WT H₂O versus APP/PS-1 H₂O, and (iii) APP/PS-1 H₂O versus APP/PS-1 NAC. A Student's t -test was used to determine statistical differences between treatment groups.

2.7 In-gel trypsin digestion

Protein spots of interest were excised from SYPRO Ruby-stained gels with a clean blade and transferred into a 0.5 mL Eppendorf microcentrifuge tube. Excised gel pieces were washed with 0.1 M NH₄HCO₃ buffer at room temperature for 15 min. ACN was added and allowed to incubate for 15 min. The mixed solution was removed and the gel pieces were allowed to dry in the tubes under a flow hood for 30 min. Next, gel pieces were incubated with 20 mM DTT in 0.1 M NH₄HCO₃ at 56°C for 45 min. The DTT solution was removed and gel pieces were incubated with 55 mM iodoacetamide in 0.1 M NH₄HCO₃ for 15 min. The solution was removed and gel pieces were incubated with 50 mM NH₄HCO₃ for 15 min, followed by the addition of ACN for 15 min. This mixed solution was removed and gel pieces were allowed to dry for 30 min in a flow hood. A solution of 20 ng/μL modified trypsin (Promega, Madison, WI, USA) in 50 mM NH₄HCO₃ was added to gel pieces in order to submerge them and were allowed to shake overnight at 37°C.

2.8 MS and database searching

Tryptic solutions were removed from gel pieces and transferred to a new microcentrifuge tube. Additional tryptic peptides were extracted from gel pieces by addition of 5 mM NH₄HCO₃ for 10 min with sonication. Next, 95% acetonitrile in 1 mM NH₄HCO₃ was added for another 10 min with sonication. This supernatant was combined with the previous tryptic solution and concentrated to a small volume (~10 μL). C18 ZipTips (Millipore, Billerica, MA, USA) were used to remove salts from samples prior to MS analysis. Samples were loaded into a 96-well plate rack for nanoelectrospray infusion using an Advion Tri-Versa Nanomate (Ithaca, NY, USA). Electro-sprayed peptides were analyzed with an LTQ-Orbitrap XL (ThermoScientific, Waltham, MA, USA) mass spectrometer. The Orbitrap was set to acquire a full MS scan at 60 000 resolution and in data-dependent mode the eight most intense ions were selected for fragmentation and mass analyzed in the Orbitrap at 30 000 resolution. Conditions for

fragmentation in the ion trap include a normalized collision energy of 35%, activation time of 30 ms, and selection of only +2 charge states or higher. Total acquisition time was 5 min per sample. SEQUEST was used for database searching against the Uniprot Swiss-Prot Database and the International Protein Index (IPI) Mouse Database and included 2 trypsin miscleavages and a fixed carbamidomethyl modification. Filter criteria of returned protein lists included protein probabilities < 0.01 , peptide XCorr values > 1.5 (for +1 charge state), 2.0 (+2 charge state), 2.5 (+3 charge state), and 3.0 (+4 charge state), peptide ΔCn values > 0.1 , and at least 2 peptides identified for each protein. Protein MW and pI information was also used to assess individual protein identifications based on the location of the excised protein spot from the 2-D gel. Only protein spots assigned to a single protein were further considered.

2.9 Western blotting

Samples (100 μg) from the 7–12-month treatment group were incubated with sample loading buffer for protein denaturation and subject to electrophoresis on a 12.5% SDS-polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane at 90 mA/gel over a 2 h period. Nitrocellulose membranes containing the transferred proteins were blocked for 1 h in fresh wash buffer (PBS, 150 mM NaCl, 0.05% Tween 20, pH 7.4) containing 3% BSA, and incubated with a 1:2000 dilution of anti-mouse enolase monoclonal antibody (Santa Cruz Biotechnologies; Santa Cruz, CA, USA) and anti-mouse actin antibody (Sigma-Aldrich) in wash buffer for 2 h. The membrane was washed 3 × in wash buffer and incubated for 1 h with a 1:8000 dilution of anti-mouse IgG HRP secondary antibody diluted in wash buffer. The membrane was washed 3 × in wash buffer and developed using chemiluminescence reagents from an ECL kit (Pierce). Blots were scanned on a phosphorimager and analyzed using ImageQuant 1D software. Actin was probed as a loading control.

3 Results

Proteomics analyses using 2-D PAGE, in-gel trypsin digestion, and MS were performed on entire brain homogenate obtained from WT and APP/PS-1 mice given drinking water or water supplemented with NAC for a period of five months. NAC treatment began at either 4 months or 7 months in order to better understand the mechanisms by which NAC provides neuroprotection against Aβ (142)-mediated protein oxidation and nitration and lipid peroxidation prior to and after amyloid deposition. Thus, for the two age groups of mice, (i.e. 9 months and 12 months) differences in global protein expression were assessed. Comparisons were as follows: (i) WT H₂O versus WT NAC,

(ii) WT H₂O versus APP/PS-1 H₂O, and (iii) APP/PS-1 H₂O versus APP/PS-1 NAC.

Figures 1 and 2A–C show examples of typical 2-D gel images of proteins isolated from the brains of WT and APP/PS-1 mice given drinking water or NAC-supplemented drinking water from 4–9 or 7–12 months of age. Protein spots that were differentially expressed between the various treatment groups (as described above) and identified with MS are labeled in the figure and listed in Tables 1 and 3. As shown in Tables 1 and 3, the probability for false protein identifications with SEQUEST was $<1e-03$ for all proteins indicating high confidence in spot assignments. Proteins were identified with at least two different peptide sequences and multiple peptide hits corresponding to every MS/MS event resulting in significant peptide identification. For example, aconitate hydratase (ACO2) was identified with six peptide sequences from 23 multiple MS/MS spectra (Table 1).

3.1 Effect of NAC on brain protein levels in WT mice

Following in vivo NAC treatment in 9-month-old WT mice, the proteins, fructose bisphosphate aldolase A (142.6 \uparrow , p -value <0.04) and superoxide dismutase 2 (SOD2) (6.75 \uparrow , p -value <0.04) were significantly increased in expression (Table 2). Prohibitin (2.95 \uparrow , p -value <0.01) was significantly increased, while cofilin 1 (0.56 \downarrow , p -value <0.04) was significantly decreased in 12-month-old WT mice (Table 4).

3.2 Comparison of WT versus APP/PS-1 mice

Several brain proteins were differentially expressed in comparisons of WT and APP/PS-1 mice given drinking water at 9 months (Table 2). Synaptosomal-associated




Figure 1. Representative 2-D gel images of differentially expressed brain proteins from the 4–9-month treatment groups in comparisons of (A) WT mice given normal drinking water or NAC-supplemented water, (B) WT mice and APP/PS-1 mice given normal drinking water, and (C) APP/PS-1 mice given normal drinking water or NAC-supplemented water. Differentially expressed proteins (i.e. ratio values of $0.67 \leq x \leq 1.5$, p -value <0.05 for $n=8$ or 9) are labeled in the images.




Figure 2. Representative 2-D gel images of differentially expressed brain proteins from the 7–12-month treatment groups in comparisons of (A) WT mice given normal drinking water or NAC-supplemented water, (B) WT mice and APP/PS-1 mice given normal drinking water, and (C) APP/PS-1 mice given normal drinking water or NAC-supplemented water. Differentially expressed proteins (i.e. ratio values of $0.67 \leq x \leq 1.5$, p -value < 0.05 for $n = 6$) are labeled in the images.

protein 25A (SNAP25 (20.5 \uparrow , p -value < 0.0003)), V-type H⁺ ATPase subunit B (16.2 \uparrow , p -value < 0.03), and cytochrome c oxidase subunit 5A (Cox5A (4.19 \uparrow , p -value < 0.02)) were significantly increased in expression. The following brain proteins were significantly decreased in APP/PS-1 compared with WT mice: ATP synthase subunit α , mitochondrial (two isoforms: 0.35 \downarrow , p -value < 0.02 ; 0.01 \downarrow , p -value < 0.02), ATP synthase subunit d, mitochondrial (0.35 \downarrow , p -value < 0.04), heat shock protein 90 α (HSP90 α (0.28 \downarrow , p -value < 0.01)), fructose-bisphosphate aldolase C (0.28 \downarrow , p -value < 0.04), ACO2, mitochondrial (0.28 \downarrow , p -value < 0.04), glyceraldehyde-3-phosphate dehydrogenase (GAPDH (0.28 \downarrow , p -value < 0.02)), α -enolase (0.02 \downarrow , p -value < 0.02), and calbindin (0.005 \downarrow , p -value < 0.0003).

Glutamine synthetase (GS) (83.9 \uparrow , p -value < 0.05) and ATP synthase subunit α , mitochondrial (4.18 \uparrow , p -value < 0.03) were significantly increased in expression in brains of 12-month-old

APP/PS-1 H₂O. Several brain proteins had decreased levels in APP/PS-1 H₂O relative to WT H₂O mice. These proteins are Cox5A (0.40 \downarrow , p -value < 0.04), hemoglobin subunit β (0.33 \downarrow , p -value < 0.02), peptidyl-prolyl *cis-trans* isomerase A (Pin1 (0.01 \downarrow , p -value < 0.004)), and dynamin 1 (0.009 \downarrow , p -value < 0.04).

3.3 Effects of NAC treatment of APP/PS-1 mice

Glutamate dehydrogenase 1 (GDH), mitochondrial (1.88 \uparrow , p -value < 0.03), was significantly increased in 9-month-old APP/PS-1 NAC mice relative to APP/PS-1 H₂O. The proteins α -enolase (60.6 \uparrow , p -value < 0.05) and pyruvate kinase isozymes M1/M2 (4.60 \uparrow , p -value < 0.005), had significantly increased levels of 12-month-old APP/PS-1 NAC mice (Table 4). Recent studies in our laboratory

investigated the expression levels of Pin1 using Western blot analysis and determined that Pin1 was significantly decreased in the brains of APP/PS-1 mice relative to WT controls [21] at 12 months of age and Pin1 levels slightly increased after in vivo NAC treatment. These results are consistent with these observations that Pin1 is significantly decreased in the brains of 12-month-old APP/PS-1 H₂O mice relative to WT H₂O mice (see Table 4).

3.4 Western blotting analysis

Western blotting analysis was performed to validate changes in protein expression for α -enolase in the 7–12-month treatment group. Figure 3A shows a Western image of three samples from each treatment group after being probed with primary enolase antibody (actin was used as a loading control). Figure 3B is a histogram plot representation of the results in which no significant changes are detected in normalized enolase expression levels across the treatment groups. However, there is a trend towards increased enolase expression in APP/PS-1 mice given drinking water treated with NAC relative to APP/PS-1 mice given drinking water. This result is generally consistent with the proteomics results reported above in Table 4. We note that the additional band most likely comes from a non-specifically bound protein. A total $n = 3$ used to measure the Western blots for enolase is small relative to the entire population of animals used in each group (i.e. $n = 8$ or $n = 9$) and could contribute to differences in the ratio differences measured by the two techniques. As noted above, one or two animals may have outlier ratios. We randomly chose a smaller subset of each group to carry out the validation study. Additionally, differences in the measured percent change in Western blots

and the 2-D gel blots could also be due to dynamic range limitations in colorimetric staining as opposed to greater sensitivity with Sypro Ruby fluorescent staining, respectively. Finally, some of the largest changes measured in 2-D gel analyses may be overestimated based on the software algorithm that estimates a threshold density value for missing or low-level spots.

4 Discussion

Substantial evidence exists that A β (1–42) significantly contributes to oxidative stress in AD and in in vitro and in vivo model systems of AD [2, 13, 37]. As a part of this ongoing work, we have investigated the levels of oxidative stress in APP/PS-1 mice [20] at ages that correlate with the start of A β deposition and plaque formation in the brain [35]. The levels of PCO, 3-NT-modified proteins, and HNE-bound proteins are increased in APP/PS-1 mice relative to WT controls [21]. Simultaneously, the increase in oxidative stress levels correlate with an increase in soluble A β , A β load, and non-neuritic and neuritic plaques [38]. We note that while A β deposits are generally localized to the hippocampus and cortex regions, we examined entire brain homogenates as beneficial effects of NAC may appear in regions other than where plaques are localized. Key to the work reported herein is the ages that were used for investigation (i.e. 4–9 month- and 7–12 month-old mice) of the effects of A β deposition and effects of in vivo NAC treatment on the brain proteome of APP/PS-1 mice. These ages correspond to animals that have similar pathology to that observed in MCI and AD patients, respectively, and correlate with periods of NAC treatment given prior to and after amyloid deposition and plaque formation.

Table 1. Proteomic identification of differentially expressed brain proteins in 4–9-month treatment groups

| Protein identified | Accession number ^{a)} | MW (kDa) | pI | Peptides (hits) ^{b)} | Probability ^{c)} |
|--|--------------------------------|----------|------|-------------------------------|---------------------------|
| Fructose-bisphosphate aldolase A | P05064 | 39 332 | 8.04 | 3 (15) | 2.00E–08 |
| Superoxide dismutase 2 | P09671 | 24 589 | 8.80 | 2 (7) | 1.00E–06 |
| Aconitrate hydratase, mitochondrial | Q99K10 | 85 411 | 7.80 | 6 (23) | 8.00E–07 |
| α -Enolase | P17182 | 47 141 | 6.37 | 2 (6) | 1.00E–05 |
| ATP synthase subunit α , mitochondrial | Q03265 | 59 753 | 9.22 | 4 (9) | 1.00E–07 |
| ATP synthase subunit α , mitochondrial | Q03265 | 59 753 | 9.22 | 3 (12) | 2.00E–07 |
| ATP synthase subunit d, mitochondrial | Q9DCX2 | 18 739 | 5.41 | 3 (9) | 5.00E–07 |
| Calbindin | P12658 | 29 976 | 4.56 | 2 (5) | 2.00E–04 |
| Cytochrome c oxidase subunit 5A, mitochondrial | P12787 | 16 092 | 6.09 | 4 (8) | 2.00E–05 |
| Fructose-bisphosphate aldolase C | P05063 | 39 371 | 6.74 | 4 (14) | 3.00E–08 |
| Glyceraldehyde-3-phosphate dehydrogenase | P16858 | 35 788 | 8.33 | 3 (11) | 1.00E–07 |
| Heat shock protein HSP 90- α | P07901 | 84 788 | 4.93 | 4 (12) | 2.00E–07 |
| Synaptosomal-associated protein 25-A | P60879 | 23 315 | 4.66 | 2 (9) | 2.00E–06 |
| V-type proton ATPase subunit B, brain isoform | P62814 | 56 516 | 5.48 | 2 (6) | 2.00E–07 |
| Glutamate dehydrogenase 1, mitochondrial | P26443 | 61 299 | 7.96 | 7 (22) | 4.00E–06 |

a) The protein accession number found in the Swiss-Prot (mouse) database.

b) The number of peptide sequences identified by ESI-MS/MS. The total number of peptide hits is indicated in (), including multiple hits across different charge states.

c) The probability associated with a false protein identification using the SEQUEST search algorithm.

Table 2. Differentially expressed proteins in 4–9-month treatment groups

| Protein identified | WT H ₂ O versus WT NAC ^{a)} | | WT H ₂ O versus APP/PS-1 H ₂ O ^{b)} | | APP/PS-1 H ₂ O versus APP/PS-1 NAC ^{c)} | |
|---|--|-----------------|---|-----------------|--|-----------------|
| | Ratio | <i>p</i> -Value | Ratio | <i>p</i> -Value | Ratio | <i>p</i> -Value |
| Fructose-bisphosphate aldolase A | 142.59 | <0.04 | | | | |
| Superoxide dismutase 2 | 6.75 | <0.04 | | | | |
| Synaptosomal-associated protein 25-A | | | 20.52 | <0.0003 | | |
| V-type proton ATPase subunit B, brain isoform | | | 16.20 | <0.03 | | |
| Cytochrome c oxidase subunit 5A, mitochondrial | | | 4.19 | <0.02 | | |
| ATP synthase subunit α , mitochondrial ^{d)} | | | 0.35 | <0.02 | | |
| ATP synthase subunit d, mitochondrial | | | 0.35 | <0.04 | | |
| Heat shock protein HSP 90- α | | | 0.28 | <0.01 | | |
| Fructose-bisphosphate aldolase C | | | 0.28 | <0.04 | | |
| Aconitate hydratase, mitochondrial | | | 0.28 | <0.04 | | |
| Glyceraldehyde-3-phosphate dehydrogenase | | | 0.28 | <0.02 | | |
| α -Enolase | | | 0.02 | <0.02 | | |
| ATP synthase subunit α , mitochondrial ^{d)} | | | 0.01 | <0.02 | | |
| Calbindin | | | 0.005 | <0.0003 | | |
| Glutamate dehydrogenase 1, mitochondrial | | | | | 1.88 | <0.03 |

a) Ratio represents the average protein spot density WT NAC/average protein spot density WT H₂O. *n* = 8 for WT H₂O and *n* = 9 for WT NAC.

b) Ratio represents the average protein spot density APP/PS-1 H₂O/average protein spot density WT H₂O. *n* = 6 for WT H₂O and *n* = 9 for APP/PS-1 H₂O.

c) Ratio represents the average protein spot density APP/PS-1 NAC/average protein spot density APP/PS-1 H₂O. *n* = 9 for each group.

d) See Fig. 1 for the location of these spots.

Table 3. Proteomic identification of differentially expressed brain proteins in 7–12-month treatment groups

| Protein identified | Accession number ^{a)} | MW (kDa) | <i>pI</i> | Peptides (hits) ^{b)} | Probability ^{c)} |
|---|--------------------------------|-----------|-----------|-------------------------------|---------------------------|
| Cofilin 1 | P18760 | 18 548.7 | 8.19 | 4 (14) | 2.00E–09 |
| Cofilin 1 | P18760 | 29 802.9 | 5.46 | 3 (9) | 6.00E–06 |
| ATP synthase subunit α , mitochondrial | Q03265 | 59 716.6 | 9.53 | 5 (17) | 2.00E–06 |
| Cytochrome c oxidase, subunit 5A | P12787 | 16 092.3 | 6.09 | 3 (11) | 1.00E–06 |
| Dynamin 1 | P39053 | 97 742.3 | 7.62 | 9 (46) | 2.00E–09 |
| Glutamine synthetase | P15105 | 42 119.65 | 6.64 | 2 (5) | 1.00E–03 |
| Hemoglobin subunit β | P02088 | 15 831.2 | 7.48 | 3 (13) | 5.00E–08 |
| Peptidyl-prolyl <i>cis-trans</i> isomerase A | P17742 | 17 971.34 | 7.73 | 2 (5) | 2.00E–05 |
| α -Enolase | P17182 | 47 112.2 | 6.38 | 7 (27) | 7.00E–08 |
| Pyruvate kinase isozymes M1/M2 | P52480 | 57 809 | 7.2 | 12 (41) | 4.00E–08 |

a) The protein accession number found in the Swiss-Prot (mouse) database.

b) The number of peptide sequences identified by ESI-MS/MS. The total number of peptide hits is indicated in (), including multiple hits across different charge states.

c) The probability associated with a false protein identification using the SEQUEST search algorithm.

Based on the proteomics results obtained, we observe several proteins whose brain levels are altered in APP/PS-1 mice relative to WT controls in both the 4–9-month and 7–12-month groups given drinking water. Below we discuss biological processes of proteins that are substantially altered in APP/PS-1 mice and where applicable, the potential benefits of NAC in influencing protein levels in WT and APP/PS-1 mice. Some of the changes reported in Tables 2 and 4 are consistent with results obtained from studies in our laboratory that have previously investigated changes to the proteomes of oxidized proteins in AD and MCI [39–43].

4.1 Energy-related enzymes

Alterations to proteins involved in various aspects of energy production through changes in expression levels or modifications could contribute to the overall dysregulation in glucose metabolism evidenced in AD [39–44]. Prior to A β (1–42) deposition (e.g. 4–9 months) the subunits of ATP synthase protein, α and d, have decreased expression in APP/PS-1 H₂O mice relative to WT H₂O mice. On the other hand, the V-type proton ATPase subunit B, which is the brain specific isoform, is increased in

Table 4. Differentially expressed proteins in 7–12-month treatment groups

| Protein identified | WT H ₂ O versus WT NAC ^{a)} | | WT H ₂ O versus APP/PS-1 H ₂ O ^{b)} | | APP/PS-1 H ₂ O versus APP/PS-1 NAC ^{c)} | |
|---|---|-----------------|--|-----------------|---|-----------------|
| | Ratio | <i>p</i> -Value | Ratio | <i>p</i> -Value | Ratio | <i>p</i> -Value |
| Prohibitin | 2.95 | <0.01 | | | | |
| Cofilin 1 | 0.56 | <0.04 | | | | |
| Glutamine synthetase | | | 83.9 | <0.05 | | |
| ATP synthase subunit α , mitochondrial | | | 4.18 | <0.03 | | |
| cytochrome c oxidase, subunit 5A | | | 0.40 | <0.04 | | |
| Hemoglobin subunit β | | | 0.33 | <0.02 | | |
| Peptidyl-prolyl <i>cis-trans</i> isomerase A | | | 0.01 | <0.004 | | |
| Dynamin 1 | | | 0.009 | <0.04 | | |
| α -Enolase | | | | | 60.6 | <0.05 |
| Pyruvate kinase isozymes M1/M2 | | | | | 4.60 | <0.005 |

a) Ratio represents the average protein spot density WT NAC/average protein spot density WT H₂O. *n* = 6 for each group.

b) Ratio represents the average protein spot density APP/PS-1 H₂O/average protein spot density WT H₂O. *n* = 6 for each group.

c) Ratio represents the average protein spot density APP/PS-1 NAC/average protein spot density APP/PS-1 H₂O. *n* = 6 for each group.




Figure 3. Western blot analysis of enolase expression in brain in the 7–12-month treatment groups. (A) Western blot image corresponding to lane 1, MWM; lanes 2–4, WT mice given normal drinking water; lanes 5–7 WT mice given NAC-supplemented water; lanes 8–10, APP/PS-1 mice given normal drinking water; and lanes 11–13, APP/PS-1 mice given NAC-supplemented water. (B) Histogram plot of enolase levels relative to percent controls (WT H₂O). The percent values are based on normalized enolase densities (i.e. density of enolase band/density of actin band). Values shown are mean \pm SD for *n* = 3.

APP/PS-1 H₂O mice relative to WT H₂O mice. In the 7–12-month-old group, ATP synthase subunit α was observed to be increased in APP/PS-1 H₂O mice relative to WT H₂O mice. ATP synthase is involved in the synthesis of ATP and work by utilizing a proton gradient that is established through the electron transport chain (ETC)

located in the inner mitochondrial membrane coupled to complex physical rotations of components of this complex [45].

Cox5A levels were increased in the brains of APP/PS-1 H₂O mice relative to WT H₂O in the 4–9-month treatment group and decreased in the 7–12-month treatment group. Cox5A is a mitochondrial enzyme involved in the final aspects of the ETC by providing reducing equivalents from cytochrome C to oxygen [46]. Elevated expression of Cox5A prior to substantial A β deposition could increase the amount of ROS present by leading to increased numbers of electrons coming out of the ETC. Alternatively, increased Cox5A expression could lead to better mitochondrial function to provide ATP. Decreased Cox5A expression however, may be an indirect or direct result of increased levels of A β deposition and correlate with increased levels of ROS and oxidative stress. It is possible that while we measure decreased Cox5A expression in the 7–12-month animals, there may be a concurrent increase in Cox5A oxidation due to increased oxidative stress. Additional experiments, such as redox proteomics, would be necessary however to support this hypothesis.

α -Enolase, fructose-bisphosphate aldolase C, GAPDH, and pyruvate kinase are enzymes important in the glycolytic and tricarboxylic acid (TCA) cycles and ATP production. Previous studies that investigated expression changes in the hippocampal region of brains from AD subjects observed significant increases in the levels of these proteins relative to age-matched controls [41]. Herein, we observed differing trends that may be a result of species differences and/or the lack of neuronal death and neurofibrillary tangles in APP/PS-1 mice. Decreased expression levels of α -enolase, fructose-bisphosphate aldolase C, and GAPDH in the brains of 4–9 month-old APP/PS-1 H₂O mice may be directly reflective of lower glucose metabolism and ATP available in the

brain. These mice have levels of A β deposition and plaque formation that are lower than that observed in 12-month-old animals whom better mimic the pathology observed in later stages of AD. Additionally, in the 7–12-month treatment group, NAC significantly increases α enolase and PK expression, suggesting that NAC through downstream mechanisms may influence certain aspects of glucose metabolism, entry into the TCA cycle, and glutamate synthesis.

4.2 Excitotoxicity

GS was reported as oxidatively modified in AD brain, [47]; thus, increased GS levels observed in 12-month-old APP/PS-1 H₂O mice could represent a cellular response to elevated glutamate as a result of A β -induced oxidative stress. GDH is a mitochondrial enzyme that catalyzes the oxidative deamination of glutamate to form α -ketoglutarate, thereby replenishing the TCA cycle. The levels of GDH do not change in APP/PS-1 H₂O mice; however, NAC indirectly or directly causes an increase in GDH in APP/PS-1 NAC mice in the 9-month-old mice. Altered glutamate regulation is observed in AD [48], and we reported oxidative modification of the glutamate transporter in AD [8]. Calbindin, a calcium-binding protein that buffers cytosolic Ca²⁺ levels, was significantly reduced in 9-month-old APP/PS-1 H₂O mice. Reduced calbindin may contribute to Ca²⁺ dyshomeostasis through increasing the levels of intracellular Ca²⁺. Other Ca²⁺-binding proteins such as calcineurin have been linked to Ca²⁺ dyshomeostasis in aging [49] and AD [50]. These data are consistent with the reports of altered Ca²⁺ levels in APP and other model systems of AD [51–53].

4.3 Cell cycle, tau phosphorylation, and A β production

Increased oxidation, decreased levels, and decreased activity of Pin1 in AD and MCI brain has been reported [54, 55]. Similarly, decreased levels and activity of Pin1 exist in the brains of APP/PS-1 H₂O mice relative to WT H₂O mice in 9- and 12-month-old mice [21]. Pin1, by binding to p-Ser/p-Thr-Pro motifs and conversion of the Pro residue of the target protein from cis-to-trans conformation and vice versa, regulates the activity of target proteins [56]. In particular, Pin1 regulates target Tau-relevant kinases and protein phosphatase 2A, important for the phosphorylation/dephosphorylation of tau, and is necessary for cell growth and proper cell cycle functions [57, 58]. Pin1 has also been implicated in A β production, in which Pin1 inhibition promotes APP processing in the amyloidogenic pathway and therefore causes elevated levels of A β [48, 59] and oxidative stress [13, 60]. This result is consistent with and may contribute to elevated numbers of

senile plaques in AD and in neuritic plaques in this APP/PS-1 model [38].

4.4 Synaptic abnormalities

One pathological hallmark of AD is synapse loss [61]. SNAP-25 is a synaptosomal protein that is a part of the Q-SNARE complex that functions in neurotransmitter release at neuronal synapses. SNAP-25 is also involved in vesicular docking and associates with proteins such as syntaxin to anchor vesicles to their target membranes. This protein is oxidatively modified in AD brain [60] and has increased levels in brains from APP/PS-1 H₂O mice relative to WT H₂O mice. SNAP-25 elevation in APP/PS-1 mice brain conceivably may be a response to oxidative stress or decreased synaptic counts or an attempt to improve neurotransmission in this mouse model of AD.

4.5 Defense systems

Heat shock protein 90 α is a molecular chaperone protein that is induced in conditions of stress response. This elevated expression serves to protect cells from damaging effects caused by stress through maintaining proper folding/unfolding of proteins. HSP90 α is significantly decreased in 9-month-old APP/PS-1 H₂O mice suggesting a lack of sufficient brain defenses in place to combat oxidative stress.

4.6 Structural proteins

Dynamamin 1 was significantly decreased in APP/PS-1 H₂O mice in the 7–12-month group. Among its functions, dynamamin is an inhibitor of phosphatidylinositol 3-kinase and has been reported to be elevated in brains of aged mice, an elevation that leads to cell death [62]. However, in AD, dynamamin mRNA and protein levels are significantly decreased and may be associated with altered synaptic vesicle recycling and endocytosis [63]. Additionally, dynamamin was also observed to be decreased in the olfactory bulbs of old mice relative to young mice which may be a regional specific expression [64]. Lower levels of dynamamin in 12-month-old APP/PS-1 H₂O mice conceivably could be related to lessened synaptic vesicle recycling due to lower numbers of synapses.

4.7 Mitochondrial proteins

With aging, the activity of ACO2, mitochondrial matrix enzyme, is altered [65, 66], and has decreased expression in aged rats [67]. ACO2 in brain is oxidatively modified in AD by the lipid peroxidation product, HNE [68]. ACO2 was

significantly decreased in the 4–9-month treatment group in APP/PS-1 H₂O mice.

4.8 Effects of NAC on the proteome of WT mice

Fructose biphosphate aldolase A and SOD2 were significantly increased in 9 month-old WT mice treated with NAC relative to WT H₂O. Fructose biphosphate aldolase A is an enzyme involved in the glycolytic pathway. SOD2, also known as MnSOD, is an antioxidant enzyme localized in the mitochondrion that protects cells from toxic superoxide anion. Elevated SOD2 upon in vivo NAC treatment in WT mice may be an early protective mechanism against augmented oxidative stress which is known to increase with aging.

In the 12-month-old age group, NAC treatment of WT mice led to prohibitin being significantly increased and cofilin 1 significantly decreased in brain. Prohibitin is localized to the inner mitochondrial membrane and is known to inhibit DNA synthesis, regulate the cell cycle, and be involved in apoptosis and aging [69]. Prohibitin has shown cellular defense against oxidative stress in epithelial cells [70, 71] and decreases in expression as a function of cellular senescence in human and chicken fibroblasts [69]. Because prohibitin also has roles as a chaperone and participates in the assembly of subunits in the mitochondrial respiratory chain complex, this protein regulates mitochondrial respiratory activity and aging [72, 73]. Elevated prohibitin expression following NAC may be helpful in delaying detrimental changes associated with mitochondrial respiration in aging by increasing the availability of components involved in the ETC. Cofilin 1 is the non-muscle isoform of cofilins that constitute a major portion of actin rods and plays roles in actin depolymerization and polymerization. Taken together, the results suggest that NAC, which many persons use as an over-the-counter dietary supplement, can affect levels of brain proteins involved in metabolism, prevention of oxidative stress, mitochondrial function, and cytoskeletal integrity. Each of these processes could be important in slowing mitochondrial alterations associated with aging.

Examining the proteomes of WT and APP/PS-1 mice given drinking water prior to (i.e. 9 months) and after (i.e. 12 months) periods of significant A β (1–42) deposition revealed several altered brain proteins involved in energy production, cell signaling, defense systems, excitotoxicity, synapse-related, cellular structure, and mitochondria in APP/PS-1 mice. In vivo NAC treatment for 5 months has been reported to provide protection against oxidative stress in brain of APP/PS-1 human double mutant knock-in mice at 9 and 12 months of age, consistent with the notion that NAC has potential to be a therapeutic approach for both MCI and AD [21]. NAC provides protection against oxidative stress because it acts as a free radical scavenger directly and increases endogenous GSH levels. Our results show that

NAC alters the expression levels of some proteins in the brain proteomes of WT and APP/PS-1 mice. It is possible larger numbers of proteins affected by NAC may be detectable in specific cell types or tissues (e.g. hippocampus and/or cortex) and global effects in brain are minimized in these studies. Studies of this nature and others that investigate the possibility for NAC as a potential therapeutic approach in MCI and AD are strongly suggested and are currently ongoing in our laboratory.

This research was supported in part by grants from NIH to D.A.B. [AG-10836; AG-05119]. R.A.S. was supported by the University of Kentucky Lyman T. Johnson Minority Postdoctoral Fellowship and a UNCF-Merck Science Initiative Postdoctoral Fellowship. She is now an Assistant Professor of Chemistry at the University of Pittsburgh.

The authors have declared no conflict of interest.

5 References

- [1] Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., Evans, D. A., Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Arch. Neurol.* 2003, *60*, 1119–1122.
- [2] Butterfield, D. A., Lauderback, C. M., Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. *Free Radic. Biol. Med.* 2002, *32*, 1050–1060.
- [3] Lovell, M. A., Gabbita, S. P., Markesbery, W. R., Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. *J. Neurochem.* 1999, *72*, 771–776.
- [4] Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D. et al., Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. *Ann. Neurol.* 1993, *34*, 609–616.
- [5] Nunomura, A., Perry, G., Pappolla, M. A., Wade, R. et al., RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. *J. Neurosci.* 1999, *19*, 1959–1964.
- [6] Wang, J., Xiong, S., Xie, C., Markesbery, W. R., Lovell, M. A., Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. *J. Neurochem.* 2005, *93*, 953–962.
- [7] Halliwell, B., Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. *Drugs Aging* 2001, *18*, 685–716.
- [8] Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N. et al., The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of A β 1-42. *J. Neurochem.* 2001, *78*, 413–416.
- [9] Markesbery, W. R., Lovell, M. A., Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. *Neurobiol. Aging* 1998, *19*, 33–36.

- [10] Beckman, K. B., Ames, B. N., The free radical theory of aging matures. *Physiol. Rev.* 1998, *78*, 547–581.
- [11] Markesbery, W. R., Oxidative stress hypothesis in Alzheimer's disease. *Free Radic. Biol. Med.* 1997, *23*, 134–147.
- [12] Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R. et al., A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N. Engl. J. Med.* 1997, *336*, 1216–1222.
- [13] Butterfield, D. A., Drake, J., Pocernich, C., Castegna, A., Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. *Trends Mol. Med.* 2001, *7*, 548–554.
- [14] Casserly, I., Topol, E., Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. *Lancet* 2004, *363*, 1139–1146.
- [15] Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K. et al., Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. *Neuron* 1997, *19*, 939–945.
- [16] Mohammad Abdul, H., Sultana, R., Keller, J. N., St Clair, D. K. et al., Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. *J. Neurochem.* 2006, *96*, 1322–1335.
- [17] Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K. et al., Familial Alzheimer's disease-linked presenilin 1 variants elevate A β 1-42/1-40 ratio in vitro and in vivo. *Neuron* 1996, *17*, 1005–1013.
- [18] van Groen, T., Kiliaan, A. J., Kadish, I., Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. *Neurobiol. Dis.* 2006, *23*, 653–662.
- [19] van Groen, T., Liu, L., Ikonen, S., Kadish, I., Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. *Neuroscience* 2003, *119*, 1185–1197.
- [20] Abdul, H. M., Sultana, R., St Clair, D. K., Markesbery, W. R., Butterfield, D. A., Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. *Free Radic. Biol. Med.* 2008, *45*, 1420–1425.
- [21] Huang, Q., Aluise, C. D., Joshi, G., Sultana, R. et al., Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. *J. Neurosci. Res.* 2010, *88*, 2618–2629.
- [22] Prescott, L. F., Park, J., Ballantyne, A., Adriaenssens, P., Proudfoot, A. T., Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. *Lancet* 1977, *2*, 432–434.
- [23] Benzi, G., Moretti, A., Are reactive oxygen species involved in Alzheimer's disease? *Neurobiol. Aging* 1995, *16*, 661–674.
- [24] Butterfield, D., Castegna, A., Pocernich, C., Drake, J. et al., Nutritional approaches to combat oxidative stress in Alzheimer's disease. *J. Nutr. Biochem.* 2002, *13*, 444.
- [25] Anderson, M. E., Luo, J. L., Glutathione therapy: from prodrugs to genes. *Semin. Liver Dis.* 1998, *18*, 415–424.
- [26] Pocernich, C. B., La Fontaine, M., Butterfield, D. A., In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. *Neurochem. Int.* 2000, *36*, 185–191.
- [27] Koppal, T., Drake, J., Butterfield, D. A., In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. *Biochim. Biophys. Acta* 1999, *1453*, 407–411.
- [28] Fontaine, M. A., Geddes, J. W., Banks, A., Butterfield, D. A., Effect of exogenous and endogenous antioxidants on 3-nitropropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. *J. Neurochem.* 2000, *75*, 1709–1715.
- [29] Pocernich, C. B., Cardin, A. L., Racine, C. L., Lauderback, C. M., Butterfield, D. A., Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. *Neurochem. Int.* 2001, *39*, 141–149.
- [30] Farr, S. A., Poon, H. F., Dogrukul-Ak, D., Drake, J. et al., The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. *J. Neurochem.* 2003, *84*, 1173–1183.
- [31] Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Eustache, F., [At the boundary between normal aging and Alzheimer disease]. *Rev. Neurol. (Paris)* 2004, *160*, S55–S63.
- [32] Petersen, R. C., Mild cognitive impairment: transition between aging and Alzheimer's disease. *Neurologia* 2000, *15*, 93–101.
- [33] Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J. et al., Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" A β sequence. *J. Biol. Chem.* 1996, *271*, 23380–23388.
- [34] Siman, R., Reaume, A. G., Savage, M. J., Trusko, S. et al., Presenilin-1 P264L knock-in mutation: differential effects on A β production, amyloid deposition, and neuronal vulnerability. *J. Neurosci.* 2000, *20*, 8717–8726.
- [35] Anantharaman, M., Tangpong, J., Keller, J. N., Murphy, M. P. et al., Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. *Am. J. Pathol.* 2006, *168*, 1608–1618.
- [36] Andreassen, O. A., Dedeoglu, A., Klivenyi, P., Beal, M. F., Bush, A. I., N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. *Neuroreport* 2000, *11*, 2491–2493.
- [37] Varadarajan, S., Yatin, S., Aksenova, M., Butterfield, D. A., Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. *J. Struct. Biol.* 2000, *130*, 184–208.

- [38] Murphy, M. P., Beckett, T. L., Ding, Q., Patel, E. et al., Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. *Neurobiol. Dis.* 2007, *27*, 301–311.
- [39] Butterfield, D. A., Gnjec, A., Poon, H. F., Castegna, A. et al., Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. *J. Alzheimers Dis.* 2006, *10*, 391–397.
- [40] Butterfield, D. A., Sultana, R., Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. *J. Alzheimers Dis.* 2007, *12*, 61–72.
- [41] Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W. M. et al., Proteomics analysis of the Alzheimer's disease hippocampal proteome. *J. Alzheimers Dis.* 2007, *11*, 153–164.
- [42] Reed, T. T., Pierce, W. M., Jr., Turner, D. M., Markesbery, W. R., Butterfield, D. A., Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. *J. Cell. Mol. Med.* 2009, *8B*, 2019–2029.
- [43] Sultana, R., Perluigi, M., Butterfield, D. A., Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. *Acta Neuropathol.* 2009, *118*, 131–150.
- [44] Pettegrew, J. W., Panchalingam, K., Klunk, W. E., McClure, R. J., Muenz, L. R., Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. *Neurobiol. Aging* 1994, *15*, 117–132.
- [45] Leyva, J. A., Bianchet, M. A., Amzel, L. M., Understanding ATP synthesis: structure and mechanism of the F1-ATPase (Review). *Mol. Membr. Biol.* 2003, *20*, 27–33.
- [46] Harris, L. K., Black, R. T., Golden, K. M., Reeves, T. M. et al., Traumatic brain injury-induced changes in gene expression and functional activity of mitochondrial cytochrome C oxidase. *J. Neurotrauma* 2001, *18*, 993–1009.
- [47] Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V. et al., Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic. Biol. Med.* 2002, *33*, 562–571.
- [48] Lee, H. G., Zhu, X., Ghanbari, H. A., Ogawa, O. et al., Differential regulation of glutamate receptors in Alzheimer's disease. *Neurosignals* 2002, *11*, 282–292.
- [49] Foster, T. C., Sharrow, K. M., Masse, J. R., Norris, C. M., Kumar, A., Calcineurin links Ca²⁺ dysregulation with brain aging. *J. Neurosci.* 2001, *21*, 4066–4073.
- [50] Sultana, R., Butterfield, D. A., Alterations of some membrane transport proteins in Alzheimer's disease: role of amyloid beta-peptide. *Mol. Biosyst.* 2008, *4*, 36–41.
- [51] Haughey, N. J., Nath, A., Chan, S. L., Borchard, A. C. et al., Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. *J. Neurochem.* 2002, *83*, 1509–1524.
- [52] Mattson, M. P., Chan, S. L., Neuronal and glial calcium signaling in Alzheimer's disease. *Cell Calcium* 2003, *34*, 385–397.
- [53] Sama, M. A., Mathis, D. M., Furman, J. L., Abdul, H. M. et al., Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. *J. Biol. Chem.* 2008, *283*, 21953–21964.
- [54] Butterfield, D. A., Poon, H. F., St Clair, D., Keller, J. N. et al., Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. *Neurobiol. Dis.* 2006, *22*, 223–232.
- [55] Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J. et al., Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. *Neurobiol. Aging* 2006, *27*, 918–925.
- [56] Lu, K. P., Finn, G., Lee, T. H., Nicholson, L. K., Prolyl cis-trans isomerization as a molecular timer. *Nat. Chem. Biol.* 2007, *3*, 619–629.
- [57] Butterfield, D. A., Abdul, H. M., Opii, W., Newman, S. F. et al., Pin1 in Alzheimer's disease. *J. Neurochem.* 2006, *98*, 1697–1706.
- [58] Lu, K. P., Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. *Prog. Cell Cycle Res.* 2000, *4*, 83–96.
- [59] Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z. et al., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. *Nature* 2006, *440*, 528–534.
- [60] Butterfield, D. A., Reed, T., Newman, S. F., Sultana, R., Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. *Free Radic Biol Med* 2007, *43*, 658–677.
- [61] Scheff, S. W., Price, D. A., Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. *Neurobiol. Aging* 2003, *24*, 1029–1046.
- [62] Poon, H. F., Vaishnav, R. A., Getchell, T. V., Getchell, M. L., Butterfield, D. A., Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. *Neurobiol. Aging* 2006, *27*, 1010–1019.
- [63] Yao, P. J., Zhu, M., Pyun, E. I., Brooks, A. I. et al., Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. *Neurobiol. Dis.* 2003, *12*, 97–109.
- [64] Poon, H. F., Vaishnav, R. A., Butterfield, D. A., Getchell, M. L., Getchell, T. V., Proteomic identification of differentially expressed proteins in the aging murine olfactory system and transcriptional analysis of the associated genes. *J. Neurochem.* 2005, *94*, 380–392.
- [65] Curti, D., Benzi, G., Age-related modification of enzyme activities in synaptosomes isolated from rat cerebral cortex. *J. Neurosci. Res.* 1989, *22*, 346–350.
- [66] Curti, D., Benzi, G., Role of synaptosomal enzymatic alterations and drug treatment in brain aging. *Clin. Neuropharmacol.* 1990, *13*, S59–S72.

- [67] Poon, H. F., Shepherd, H. M., Reed, T. T., Calabrese, V. et al., Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. *Neurobiol. Aging* 2006, 27, 1020–1034.
- [68] Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F. et al., Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. *Proteomics Clin. Appl.* 2009, 3, 682–693.
- [69] Coates, P. J., Nenutil, R., McGregor, A., Picksley, S. M. et al., Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. *Exp. Cell Res.* 2001, 265, 262–273.
- [70] Theiss, A. L., Idell, R. D., Srinivasan, S., Klapproth, J. M. et al., Prohibitin protects against oxidative stress in intestinal epithelial cells. *FASEB J.* 2007, 21, 197–206.
- [71] Theiss, A. L., Vijay-Kumar, M., Obertone, T. S., Jones, D. P. et al., Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. *Gastroenterology* 2009, 137, 199–208, 208 e191–e196.
- [72] Nijtmans, L. G., Artal, S. M., Grivell, L. A., Coates, P. J., The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. *Cell Mol. Life Sci.* 2002, 59, 143–155.
- [73] Nijtmans, L. G., de Jong, L., Artal Sanz, M., Coates, P. J. et al., Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. *EMBO J.* 2000, 19, 2444–2451.